Forma Therapeutics and Janssen Biotech Target Tumour Metabolism with US$700 M Drug Discovery Alliance

Abstract

Forma Therapeutics has secured another big pharma deal by forming a cancer drug discovery alliance with Johnson & Johnson’s Janssen Biotech. Forma will discover and develop drugs against a panel of tumour metabolism targets and could receive up to US$700 M in project funding and milestone payments plus royalties. In a first for the company and contingent upon the achievement of certain milestones during the initial phase of the collaboration, Forma has an option to co-develop and retain North American rights to one of the collaboration programmes, to be selected by Janssen.